{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:46:03Z","timestamp":1776851163364,"version":"3.51.2"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Chronic eosinophilic pneumonia (CEP) presents eosinophil infiltrations in the lung due to allergic reactions. Most CEP patients continue to take glucocorticoids, and their prolonged use induces various side effects. In this case report, based on the efficacy of baricitinib in patients with rheumatoid arthritis (RA) and CEP, we aimed to show that the administration of Janus kinase (JAK) inhibitors, when RA is complicated by an allergic disease, can stabilize the disease state and help avoid the adverse effects of long-term systemic glucocorticoid administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients concerns:<\/jats:title>\n            <jats:p>A 56-year-old woman developed RA at the age of 19 years. Treatment of the arthritis was initiated, but the joint destruction had progressed. At the age of 42, she developed eosinophilic pneumonia, which was relieved by glucocorticoid therapy. Since then, maintenance therapy has been continued with the diagnosis of CEP. She was treated with concomitant tacrolimus for persistent arthritis, and the prednisolone (PSL) dose was reduced to 3\u2009mg\/day after 10 years. However, around this time, an increase in peripheral blood eosinophil counts and respiratory symptoms was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The peripheral blood eosinophil count was 4000\/\u00b5L and computed tomography revealed multiple ground-glass opacities in the peripheral lung fields. As interstitial pneumonia due to infection or other causes was ruled out, CEP relapse was diagnosed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Pneumonia rapidly recovered when the PSL dose was increased to 15\u2009mg\/day, and asymptomatic eosinophilic infiltrates reappeared in the lung field along with a relapse of arthritis when the PSL dose was reduced to 5\u2009mg\/day. Concomitant use of methotrexate and baricitinib has been introduced to suppress allergic reactions to pneumonia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After starting combination therapy with baricitinib and methotrexate, both arthritis and eosinophilia improved, and glucocorticoid-free remission was achieved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Recently, inhibition of IL-5 signaling via JAK2 has been reported to be effective in bronchial asthma and atopic dermatitis. Although complications of RA and CEP are not common, the actions of baricitinib are useful not only in arthritis but also in allergic diseases. The efficacy of some JAK inhibitors should be actively tested in patients with RA and these complications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033396","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T15:02:47Z","timestamp":1680274967000},"page":"e33396","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A case of chronic eosinophilic pneumonia associated with rheumatoid arthritis in glucocorticoid-free remission with JAK inhibitor: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-5933","authenticated-orcid":false,"given":"Takashi","family":"Yamane","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kakogawa Central City Hospital, Kakogawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hashiramoto","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.amjms.2017.03.020","article-title":"Eosinophilic lung disease.","volume":"354","author":"Jonathan","year":"2017","journal-title":"Am J Med Sci"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.chest.2017.03.001","article-title":"Acute eosinophilic pneumonia: correlation of clinical characteristics with underlying cause.","volume":"152","author":"De Giacomi","year":"2017","journal-title":"Chest"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.alit.2017.12.004","article-title":"Long-term management and persistent impairment of pulmonary function in chronic eosinophilic pneumonia: a review of the previous literature.","volume":"67","author":"Suzuki","year":"2018","journal-title":"Allergol Int"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e1003432e1003432","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study.","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update.","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/annrheumdis-2021-221323","article-title":"Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.","volume":"81","author":"Lopez-Romero","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials.","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"114690","DOI":"10.1016\/j.bcp.2021.114690","article-title":"The JAK1\/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.","volume":"192","author":"Luschnig","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaci.2022.03.030","article-title":"Atopic dermatitis and risk of autoimmune conditions: population-based cohort study.","volume":"150","author":"de Lusignan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.semarthrit.2020.07.015","article-title":"Patients with asthma have a higher risk of rheumatoid arthritis: a systematic review and meta-analysis.","volume":"50","author":"Charoenngam","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R11-20250504","first-page":"833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma.","volume":"22","author":"Dalal","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2020-5-3","DOI":"10.7573\/dic.2020-5-3","article-title":"Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance.","volume":"9","author":"Kisling","year":"2020","journal-title":"Drugs Context"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/JAA.S342993","article-title":"Development of rheumatoid arthritis during anti-interleukin-5 therapy in a patient with refractory chronic eosinophilic pneumonia.","volume":"14","author":"Kawabata","year":"2021","journal-title":"J Asthma Allergy"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jbspin.2010.02.042","article-title":"Chronic eosinophilic pneumonia (Carrington\u2019s disease) and rheumatoid arthritis.","volume":"77","author":"Boudou","year":"2010","journal-title":"Joint Bone Spine"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1900476","DOI":"10.1183\/13993003.00476-2019","article-title":"Allergic diseases and long-term risk of autoimmune disorders: longitudinal cohort study and cluster analysis.","volume":"54","author":"Krishna","year":"2019","journal-title":"Eur Respir J"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13075-019-2035-3","article-title":"Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis.","volume":"21","author":"Zaccardelli","year":"2019","journal-title":"Arthritis Res Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:14:56Z","timestamp":1746324896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":16,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033396","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}